Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-06-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
独立董事关于第三届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding a specific board meeting agenda item about the sale of a subsidiary's 100% equity. It references compliance with regulatory guidelines and internal company rules, and it discusses the fairness and approval process of the transaction. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is not a voting result announcement or a proxy solicitation. It is a formal management/board-related opinion on a transaction matter, which fits best under Board/Management Information (MANG) as it relates to board meeting matters and decisions. The document length is short and focused on board opinions, not a full report or announcement of a report publication.
2020-06-14 Chinese
关于召开2020年第二次临时股东大会的通知（已取消）
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed notice about convening the 2020 second extraordinary general meeting of shareholders for 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes information about the meeting date, time, venue, voting procedures (both in-person and online), registration details, agenda items to be voted on, and instructions for shareholders. It also contains attachments such as proxy forms, shareholder registration forms, and voting instructions. There is no financial data or results reported, nor is it a transcript or presentation. The document is clearly a formal announcement to shareholders about the upcoming shareholders' meeting and the related voting process. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or proxy statement itself, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it includes detailed voting instructions and proxy forms for shareholders to exercise their voting rights at the meeting. Confidence is high given the detailed procedural content and the nature of the document as a meeting notice with voting instructions.
2020-06-14 Chinese
独立董事关于第三届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a specific board meeting agenda item about the sale of a subsidiary's 100% equity. It references regulatory guidelines for independent directors and the board meeting process. The content is focused on governance and board-level approval of a transaction, not on financial results, audit, or shareholder voting outcomes. The document length is short (793 characters) and it is a pre-approval opinion rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2020-06-14 Chinese
关于贝伐珠单抗注射液（MIL60）上市许可申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the acceptance of their new drug application for 贝伐珠单抗注射液 (MIL60) by the National Medical Products Administration (国家药品监督管理局). It details the receipt of the acceptance notice, basic information about the drug, and the impact and risk warnings related to the application process. The document is short (1343 characters) and serves as an official announcement of a regulatory event rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report but an announcement of a regulatory acceptance notice. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-14 Chinese
公司章程（2020年6月）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Betta Pharmaceuticals Co. Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance matters. It references the Company Law of the People's Republic of China and Securities Law, and includes detailed chapters on shareholders, board of directors, management, supervisory board, financial accounting, profit distribution, and amendments to the articles. The document is a comprehensive governance document that sets out the internal rules and structure of the company rather than a financial report, announcement, or meeting material. It is not an Annual Report, Interim Report, Earnings Release, nor a Proxy Statement or Voting Results. It is not a regulatory filing or legal proceeding update. The content matches the definition of Governance Information (CGR), which details the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary.
2020-06-14 Chinese
公司章程修正案
Governance Information Classification · 95% confidence The document is titled '章程修正案' which translates to 'Articles of Association Amendment'. It details proposed amendments to the company's articles of association, including governance structure, shareholder rights, and board responsibilities. The text references compliance with securities laws and regulations, and it states that the amendments require approval at a shareholders' meeting. The document is a formal proposal for changes to the company's governance documents rather than a report of financial results, management discussion, or an announcement of voting results. It is not a full annual or interim report, nor is it a certification or a brief announcement. The content fits best under Governance Information (CGR), as it details the company's internal rules and governance practices.
2020-06-14 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.